Table 1.
Demographic and baseline clinical characteristics of the patients with moderate‐to‐severe rheumatoid arthritis in each treatment groupa
| Characteristic | SB5 (n = 271) | ADA (n = 273) |
|---|---|---|
| Mean ± SD age, years | 49.8 ± 12.67 | 52.5 ± 11.91 |
| Sex, no. (%) | ||
| Female | 217 (80.1) | 224 (82.1) |
| Male | 54 (19.9) | 49 (17.9) |
| Race, no. (%) | ||
| White | 271 (100) | 269 (98.5) |
| Asian | 0 (0.0) | 4 (1.5) |
| BMI, mean ± SD kg/m2 | 26.2 ± 4.76 | 27.0 ± 5.10 |
| Rheumatoid factor positive, no. (%) | 203 (74.9) | 185 (67.8) |
| Disease duration, mean ± SD years | 5.4 ± 4.4 | 5.5 ± 4.3 |
| Weekly methotrexate dose, mean ± SD mg | 15.13 ± 4.62 | 15.35 ± 4.41 |
| Swollen joint count, mean ± SD | 15.8 ± 8.03 | 15.5 ± 7.54 |
| Tender joint count, mean ± SD | 23.9 ± 11.69 | 24.1 ± 10.82 |
| CRP, mean ± SD mg/ml | 11.5 ± 19.04 | 12.6 ± 18.99 |
| ESR, mean ± SD mm/hour | 39.6 ± 13.27 | 39.6 ± 13.86 |
| HAQ DI score, mean ± SD | 1.3 ± 0.61 | 1.4 ± 0.64 |
| VAS score, mean ± SD mm | ||
| Pain | 59.2 ± 20.70 | 60.8 ± 19.71 |
| Patient's global assessment | 58.5 ± 20.29 | 59.4 ± 18.65 |
| Physician's global assessment | 59.8 ± 16.87 | 60.6 ± 15.38 |
| DAS28‐ESR, mean ± SD | 6.5 ± 0.74 | 6.5 ± 0.71 |
a
ADA = reference adalimumab; BMI = body mass index; CRP = C‐reactive protein; ESR = erythrocyte sedimentation rate; HAQ DI = Health Assessment Questionnaire disability index; VAS = visual analog scale; DAS28‐ESR = Disease Activity Score in 28 joints based on the ESR.